Micronised Resveratrol as a Treatment for Friedreich Ataxia

ClinicalTrials.gov Identifier: NCT03933163. May 1, 2019


Phase 2. 40 participants, Double-blind, randomised, placebo-controlled 2-period crossover trial of 2g/day of micronised resveratrol versus placebo. Participants will be randomised in terms of the order in which they received micronised resveratrol and placebo.
The study will be a double-blinded, placebo-controlled randomised 2-period crossover trial of 2g/day of micronised resveratrol in FRDA over 24 weeks. The study will enrol 40 patients with FRDA from 3 sites. The primary outcome measure is the change in modified Friedreich Ataxia Rating Scale (mFARS) score from baseline to 24 weeks.
Sponsors and Collaborators: Murdoch Childrens Research Institute
Locations: Queensland, Victoria, Western Australia (Australia)

Micronised Resveratrol as a Treatment for Friedreich Ataxia